[go: up one dir, main page]

EP1509614A4 - Inhibiteurs de la proteine kinase associee aux membranes en tant que regulateurs de l'expression de l'antigene specifique de tumeurs - Google Patents

Inhibiteurs de la proteine kinase associee aux membranes en tant que regulateurs de l'expression de l'antigene specifique de tumeurs

Info

Publication number
EP1509614A4
EP1509614A4 EP03717900A EP03717900A EP1509614A4 EP 1509614 A4 EP1509614 A4 EP 1509614A4 EP 03717900 A EP03717900 A EP 03717900A EP 03717900 A EP03717900 A EP 03717900A EP 1509614 A4 EP1509614 A4 EP 1509614A4
Authority
EP
European Patent Office
Prior art keywords
regulators
inhibitors
membrane
protein kinase
specific antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03717900A
Other languages
German (de)
English (en)
Other versions
EP1509614A1 (fr
Inventor
James T Kurnick
Paul J Durda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1509614A1 publication Critical patent/EP1509614A1/fr
Publication of EP1509614A4 publication Critical patent/EP1509614A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03717900A 2002-02-15 2003-02-18 Inhibiteurs de la proteine kinase associee aux membranes en tant que regulateurs de l'expression de l'antigene specifique de tumeurs Withdrawn EP1509614A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35758602P 2002-02-15 2002-02-15
US357586P 2002-02-15
PCT/US2003/004786 WO2004087941A1 (fr) 2002-02-15 2003-02-18 Inhibiteurs de la proteine kinase associee aux membranes en tant que regulateurs de l'expression de l'antigene specifique de tumeurs

Publications (2)

Publication Number Publication Date
EP1509614A1 EP1509614A1 (fr) 2005-03-02
EP1509614A4 true EP1509614A4 (fr) 2007-09-12

Family

ID=33130319

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03717900A Withdrawn EP1509614A4 (fr) 2002-02-15 2003-02-18 Inhibiteurs de la proteine kinase associee aux membranes en tant que regulateurs de l'expression de l'antigene specifique de tumeurs

Country Status (4)

Country Link
EP (1) EP1509614A4 (fr)
AU (1) AU2003222221A1 (fr)
CA (1) CA2475206A1 (fr)
WO (1) WO2004087941A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
WO2008082730A2 (fr) * 2006-09-19 2008-07-10 Novartis Ag Biomarqueurs de modulation cible, efficacité, diagnostic et/ou pronostic pour les inhibiteurs de la raf
JP5397692B2 (ja) * 2007-11-28 2014-01-22 国立大学法人名古屋大学 悪性黒色腫抗原の発現上昇剤及びその用途
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2011156970A1 (fr) * 2010-06-18 2011-12-22 Xu Zhiheng Utilisations d'un mtea dans le diagnostic et le traitement d'une tumeur maligne
EP2665835B1 (fr) * 2011-01-18 2018-03-14 Everist Genomics, Inc. Signature pronostique de la récurrence d'un cancer colorectal
WO2013001372A2 (fr) * 2011-06-30 2013-01-03 University Of Oslo Procédés et compositions pour inhiber l'activation des lymphocytes t régulateurs
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
EP2971045B1 (fr) 2013-03-13 2019-06-19 Health Research, Inc. Compositions et procédés pour l'utilisation de récepteurs de lymphocytes t recombinants pour la reconnaissance directe d'un antigène tumoral
WO2016168264A1 (fr) * 2015-04-13 2016-10-20 Kiromic, Llc Méthodes et compositions pour traiter un cancer avec des cellules dendritiques
CN114686433A (zh) * 2020-12-28 2022-07-01 华中科技大学 一种小鼠三阴型原发胶质母细胞瘤细胞株及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017952A2 (fr) * 2000-09-01 2002-03-07 Van Andel Institute Inhibition de la voie de la proteine mapkkk: une strategie therapeutique selective contre les melanomes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017952A2 (fr) * 2000-09-01 2002-03-07 Van Andel Institute Inhibition de la voie de la proteine mapkkk: une strategie therapeutique selective contre les melanomes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KONO MICHIHIRO ET AL: "Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.", MOLECULAR CANCER RESEARCH : MCR OCT 2006, vol. 4, no. 10, October 2006 (2006-10-01), pages 779 - 792, XP002433088, ISSN: 1541-7786 *
KOO H-M ET AL: "Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 5, 5 March 2002 (2002-03-05), pages 3052 - 3057, XP002225753, ISSN: 0027-8424 *
KURNICK J T ET AL: "A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 AUG 2001, vol. 167, no. 3, 1 August 2001 (2001-08-01), pages 1204 - 1211, XP002433087, ISSN: 0022-1767 *
See also references of WO2004087941A1 *

Also Published As

Publication number Publication date
EP1509614A1 (fr) 2005-03-02
AU2003222221A1 (en) 2004-10-25
CA2475206A1 (fr) 2003-08-15
WO2004087941A1 (fr) 2004-10-14

Similar Documents

Publication Publication Date Title
DE60334460D1 (de) Antikörper spezifisch für das tau-protein des zentralen nervensystems
CY2016035I2 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
BRPI0415230A (pt) anticorpo biespecìfico de substituição de proteìnas funcionais
ATE419849T1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
EP1511730B8 (fr) Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
EP1601373A4 (fr) Liberation intracellulaire de petites molecules, d'acides nucleiques et de proteines
MX2019005150A (es) Inhibidores de la tirosina-cinasa de bruton.
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
EP1509614A4 (fr) Inhibiteurs de la proteine kinase associee aux membranes en tant que regulateurs de l'expression de l'antigene specifique de tumeurs
DE60117568D1 (de) Kondensierte pyrazol derivate als protein kinase inhibitoren
PL1957539T3 (pl) Ludzkie przeciwciała monoklonalne przeciwko białku kinazy tyrozynowej 7 (PTK7) i ich zastosowanie
EP1674480A4 (fr) Anticorps capable de reconnaitre la region de controle de l'activation de tgf-beta
DK1572946T3 (da) Terapeutisk humant monoklonalt anti-IL-1R1-antistof
EP1542721A4 (fr) Anticorps "s" modifies
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas
DE60207053D1 (de) Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
DE60229961D1 (de) Antikörper enthaltende stabilisierte zubereitungen
EP1642969A4 (fr) Proteine fluorescente et proteine pigment
BR0316544A (pt) Compostos calcilìticos
ATE393160T1 (de) Derivative von 9,10-dihydro-9-oxa-10- phosphaphenanthren-10-oxid
DE50214750D1 (de) Kinase inhibitoren und deren verwendung
ATE382062T1 (de) Antikörper gegen allgegenwärtige mitochondriale kreatinkinase und dessen verwendung
EP2002005A4 (fr) Identification de la protéine crmp4 en tant que régulateur convergent de l'inhibition de la croissance des axones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040831

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20070810

17Q First examination report despatched

Effective date: 20071112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080523